Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation
NEW DELHI, April 13 (Reuters) - Pfizer Inc (PFE.N) said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech (22UAy.DE) to India after the government eased import rules, after withdrawing its application in February.
"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email. read more
"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government’s immunisation program."
Our Standards: The Thomson Reuters Trust Principles.